Welcome to our dedicated page for Xilio Therapeutics SEC filings (Ticker: XLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xilio Therapeutics, Inc. (Nasdaq: XLO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Xilio is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies, and its filings offer detailed information on clinical progress, collaborations, financings, governance and listing status.
Through this page, readers can review current reports on Form 8-K in which Xilio reports material events such as pipeline and business updates, clinical trial milestones, collaboration developments with partners like Gilead, Roche and AbbVie, financings and warrant exercises, cash runway estimates, Nasdaq listing matters and changes in board leadership. Filings also describe events such as the initiation of Phase 2 dosing for efarindodekin alfa (XTX301), late-breaking data for vilastobart in microsatellite stable metastatic colorectal cancer, and approvals of equity incentive plans and stock option repricings by stockholders.
Investors can also consult proxy statements on Schedule 14A to understand proposals submitted to stockholders, including equity plan approvals and adjournment proposals, as well as the mechanics of special meetings. Other periodic reports, such as Forms 10-Q and 10-K when available, provide additional context on research and development expenses, collaboration and license revenue, net loss and risk factors related to Xilio’s clinical-stage operations and Nasdaq listing compliance.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as updated financial guidance, listing notifications, and the implications of collaboration terms or option milestones. Users can quickly identify disclosures on topics like cash and cash equivalents, stockholders’ equity, minimum bid price grace periods, and the structure of development and commercialization options under Xilio’s license agreements. This makes it easier to interpret lengthy SEC documents and understand how Xilio’s masked immuno-oncology strategy is reflected in its regulatory reporting.
Xilio Therapeutics is asking stockholders to elect four Class II directors, ratify Ernst & Young LLP as independent auditor, and approve an amended 2021 stock incentive plan at its virtual 2026 annual meeting.
The stock plan change would revise the evergreen formula so annual share increases from 2027 through 2031 are based on 5% of both outstanding common stock and shares underlying prefunded warrants, subject to board discretion. As of April 16, 2026, common stock outstanding was 5,982,839 shares and prefunded warrants outstanding were 13,107,620. Audit fees to Ernst & Young LLP totaled $1,127,220 for 2025. The proxy also describes a prior 1-for-14 reverse stock split and current equity overhang and burn-rate metrics.
Xilio Therapeutics director Cheryl R. Blanchard received a grant of stock options covering 10,000 shares of common stock. These options have an exercise price of $8.40 per share and expire on April 14, 2036.
The award was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, as long as she continues to serve the company through each vesting date. Following this grant, she holds 10,000 options directly.
Xilio Therapeutics, Inc. filed an initial insider ownership report for director Cheryl R. Blanchard. This Form 3 identifies her status as a director of the company but shows no reported stock transactions or derivative positions at the time of filing.
Xilio Therapeutics, Inc. reported a board change and related director compensation details. On April 15, 2026, the board elected Cheryl R. Blanchard, Ph.D. as a Class III director with a term running through the 2027 annual meeting, and appointed her chair of the Compensation Committee and a member of the Audit Committee.
She will receive an annual cash fee of $40,000 for board service, plus $12,000 as Compensation Committee chair and $7,500 as an Audit Committee member. She will also receive an initial option to purchase 10,000 shares, vesting over three years, and become eligible for annual options to purchase 5,000 shares after six months of service. Each option will carry an exercise price equal to the Nasdaq closing price on the grant date and a ten-year term.
Dr. Blanchard replaces Christina Rossi, who resigned from the board and all committees effective April 15, 2026. The company states that Ms. Rossi’s resignation did not result from any disagreement with the company or its management.
Xilio Therapeutics, Inc. director Shannon James Samuel completed an open-market purchase of common stock. On March 26, 2026, Samuel bought 5,000 shares at a weighted average price of $8.79 per share, increasing direct holdings to 10,000 shares. The reported ownership reflects a 1-for-14 reverse stock split effective March 13, 2026.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on masked immuno-oncology therapies that activate mainly inside tumors to improve cancer outcomes while limiting side effects. The company implemented a 1‑for‑14 reverse stock split of its common stock on March 13, 2026.
Xilio’s pipeline includes XTX501, a bispecific PD‑1/masked IL‑2 antibody fusion protein expected to enter Phase 1 after an IND filing targeted for mid‑2026, and two wholly owned masked T‑cell engager programs directed at PSMA/STEAP1 and CLDN18.2 with planned IND submissions in 2027. Efarindodekin alfa, a masked IL‑12, showed early anti‑tumor activity and tolerability in Phase 1 and is in an ongoing Phase 2 trial.
The company has major collaborations: with Gilead for efarindodekin alfa and other IL‑12 molecules, with up to $575 million in potential milestones plus royalties, and with AbbVie on up to four masked immunotherapy programs, with up to about $2.1 billion in potential contingent payments plus royalties. As of June 30, 2025, non‑affiliate common stock held an aggregate market value of about $34.9 million, and 5,782,511 shares were outstanding as of March 18, 2026.
Xilio Therapeutics reported much stronger 2025 results driven by collaboration revenue and new financing, while outlining progress across its masked immuno-oncology pipeline. Collaboration and license revenue rose to $43.8 million in 2025 from $6.3 million in 2024, mainly from AbbVie and Gilead agreements.
Research and development spending increased to $56.0 million as the company advanced XTX501 and multiple masked T cell engager programs, and net loss narrowed to $35.0 million from $58.2 million. Cash and cash equivalents were $137.5 million as of December 31, 2025, and Xilio expects this to fund operations through the end of 2027.
Xilio Therapeutics is implementing a 1-for-14 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026. Every fourteen issued and outstanding shares will be automatically reclassified into one share, with cash paid instead of fractional shares.
The company expects its common stock to begin trading on a split-adjusted basis on March 16, 2026 under the existing symbol XLO. The reverse split will not change the number of authorized shares or the par value but will reduce outstanding shares from approximately 73.5 million to approximately 5.2 million. A key aim is to help regain compliance with the Nasdaq Capital Market minimum bid price requirement.
Xilio Therapeutics is sharing an updated investor presentation highlighting its tumor‑selective immuno‑oncology pipeline, strategic partnerships and cash position. The company reports an estimated $137 in cash and cash equivalents as of December 31, 2025, plus $40M in gross proceeds from a February 2026 follow‑on offering and a cash runway through the end of 2027.
The presentation emphasizes wholly owned and partnered programs, including bispecific PD‑1/masked IL‑2 candidate XTX501, masked T cell engagers targeting PSMA+STEAP1 and CLDN18.2, masked IL‑12 efarindodekin alfa with Gilead, and masked anti‑CTLA‑4 vilastobart. Xilio outlines potential additional funding sources, including up to $36 in gross proceeds from Series C warrant exercises and a $75M option fee if Gilead licenses the IL‑12 program, alongside milestones with AbbVie and Gilead through 2027.